Health Alert: FDA advisers recommend approval of ALS drug, increasing likelihood the agency will clear the hotly debated treatment

The vote was a stunning turnaround from late March when the panel voted 6 to 4 against recommending approval of the drug, which has strong support from patients with the fatal neurodegenerative disease and their doctors. The FDA, which usually follows the advisory panel's recommendation but is not required to, is expected to decide on the treatment by Sept. 29. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

Sign up for alerts Health Alert Sept. 7, 7:06 p.m. EDT FDA advisers recommend approval of ALS drug, increasing likelihood the agency will clear the hotly debated treatment The vote was a stunning turnaround from late March when the panel voted 6 to 4 against recommending approval of the drug, which has strong support from patients with the fatal neurodegenerative disease and their doctors. The FDA, which usually follows the advisory panel's recommendation but is not required to, is expected to decide on the treatment by Sept. 29. Read more   Advertisement

Manage my email newsletters and alerts | Unsubscribe | Privacy Policy | Help You received this email because you signed up for news alerts or because it is included in your subscription. ©2022 The Washington Post | 1301 K St NW, Washington DC 20071